Loading organizations...
§ Venture Capital · 118 SCIARAPPA ST. NO. 2, Cambridge, MASSACHUSETTS, 02141
Venture capital firm investing in U.S. biopharma for oncology, neurology, and immunology, targeting IND-Phase 2 therapies.
Dreavent 6 is a Cambridge, Massachusetts-based venture capital firm that invests in emerging biopharmaceutical companies developing therapies for oncology, neurology, immunology, and metabolic diseases. The firm targets clinical-stage biotechnology businesses operating from the Investigational New Drug phase through Phase 2 trials, specifically participating in Series A through Series C funding rounds. Operating with a team of eight employees, the firm manages ten closed funds dedicated to advancing novel therapeutics. Dreavent 6 frequently co-invests in these life sciences assets alongside major pharmaceutical corporations such as Eli Lilly and Merck. The firm's active investment portfolio includes clinical-stage developers like Elicio Therapeutics, Chimeron Bio, and Aardvark Therapeutics, the latter of which recently raised an $85 million Series C round. The organization was founded in 2020 by a leadership team that includes managing partners Gorka Fius and Wendy Nelson.
Dreavent 6 has 1 tracked investment across 1 company. The latest tracked deal is $55.0M Series D in Rgenix in July 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2022 | Rgenix | $55.0M Series D | Vivo Capital, Michael Ginder | VenBio Partners, Lepu Medical, Novo Holdings, Partnership Fund For NEW York City, Sixty Degree Capital, Sofinnova Partners |